Since early August, the world’s most valuable pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), has put on a stellar performance. After tanking 14% on Aug. 7 due to poor clinical trial results, ...
Eli Lilly and Company’s LLY stock crossed the $1000 per share mark for the first time on Nov. 12, reaching new highs. It is also fast nearing the $1 trillion market cap benchmark. The key driver of ...
GSK gets an entry in the list with Exdensur (depemokimab), a twice-yearly injectable IL-5 inhibitor for severe asthma, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results